A Phase I, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate KP405. Part 1: Single Ascending Dosing in Healthy Participants. Part 2: Multiple Ascending Dosing in Healthy Participants and Parkinson's Disease Patients.
Latest Information Update: 10 Mar 2025
At a glance
- Drugs KP 405 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Kariya Pharmaceuticals
Most Recent Events
- 07 Mar 2025 Status changed from not yet recruiting to recruiting.
- 06 Apr 2024 Planned End Date changed from 31 Mar 2025 to 31 Mar 2026.
- 06 Apr 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.